Read about Benitec in the news, events and developments in the RNAi industry below. For details of Benitec's announcements to the ASX, read details in our Investor Centre.


Benitec Mid-Year Shareholder Update 05-Jul-2017
Nature: OPMD data published in Nature Communications 31-Mar-2017
BioWorld: Aussie firm Benitec gets new life via Nantworks deal 21-Feb-2017


Seeking Alpha : Benitec Bio to collaborate with NantVentures in cancer-focused R&D 24-Oct-2016
Fierce BioTech : Soon-Shiong swoops in on Benitec for PhII gene-silencing data 24-Oct-2016
Gen News : Benitec, NantVentures Launch Oncology R&D Collaboration 24-Oct-2016
In vivo OPMD data presented at BSGCT meeting 15-Apr-2016
Benitec Comments on CSHL IP Activity 13-Apr-2016


Benitec’s CEO interviewed by Alan Kohler for Eureka Report 01-May-2015
CSIRO maintains foundational patent for RNAi gene silencing technology – CSIRO 02-Mar-2015
Institutional Investors Wary of Early Stage Biotech Firms - The Australian 23-Feb-2015
Benitec’s CEO featured in February The CEO Magazine 01-Feb-2015
Benitec’s progress with programs and partnering featured in MergerMarket 27-Jan-2015


PR Newswire: Global RNAi therapeutics market to reach $1.2b by 2020 09-Sep-2014
Bioshares: “Evidence of ddRNAi therapy correctly activating liver cells” in HCV clinical trial 05-Sep-2014
The Scientist: The Second Coming of RNAi 01-Sep-2014
Benitec's CBO speaks with Sky Business News 17-Aug-2014
Benitec’s licensee Calimmune featured on PBS NewsHour on HIV/AIDS 07-Feb-2014
Benitec features in QANTAS ‘The Australian Way’ magazine 06-Jan-2014


The Australian: Biotech firm offers remedy for carmaker void 19-Dec-2013
Benitec in BRW’s Top 5 Trend ‘Biotech boat lifted in buoyant markets’ in 2013 17-Dec-2013
Benitec's CEO on New York-based O Six News 16-Dec-2013
Benitec’s CEO on 4BC ‘Health & Well being’ 15-Dec-2013
Bioshares: Benitec’s technology risk ‘very high’ but ‘very likely exceeded by potential’ 13-Dec-2013
Lodge Partners says FDA review is ‘low risk’ and recommends ‘buy’ 02-Dec-2013
Benitec in ‘7 biotech stocks with bounding share prices’ – The Bull 18-Nov-2013
Calimmune's CSO presents HIV clinical trial update to Benitec Sydney Shareholder Session 15-Nov-2013
MergerMarket says Benitec could see partnership interest next year 13-Nov-2013
Benitec featured in the Ahead Of The Curve magazine 01-Oct-2013
TT-034 selected for pre-eminent Liver Disorders conference 05-Aug-2013
Renub Research: Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide 29-Jul-2013
Hepatitis C Research & News: FDA puts ‘partial hold’ on Vertex study 26-Jul-2013
Benitec raises $7m for hep C treatment after 6 year patent war (BRW) 17-Jun-2013
Advance Abstract: Local injection of lentivirus encoding LINGO-1 shRNA promotes functional recovery in rats 17-Jun-2013
Freehills Update : US Supreme Court Decision on Myriad’s Gene Patent- Implications for Australian Applicants 14-Jun-2013
TT-034 Clinical Trial Protocol - RAC Jun 2013 12-Jun-2013
Yahoo Finance: uniQure to Receive EUR 2.5 Million Grant for RNAi Gene Therapy for Huntington's Disease 21-May-2013
UCSD selected as site for HCV ‘in-human’ trials 17-Apr-2013
RAC submission moves HCV closer to the clinic 16-Apr-2013
Genable gains Orphan Drug status for eye treatment 15-Apr-2013
Former CEO of Cephalon Joins Benitec’s Board 11-Apr-2013


Benitec Presents at US 6th Annual Pain Therapeutics Summit 13-Dec-2012
BLT Ausbiotech Presentation Nov 2012 31-Oct-2012
ddRNAi – The New Therapeutic Revolutions? Benitec Presentation Australian Microcap Investment Conference 17-Oct-2012
Presentation San Jose Pain Therapeutics Summit & San Francisco Investor Forum 02-Oct-2012
Benitec Strategy Update: Pathways to Revenue 25-Sep-2012
Hepatitis B Program Meeting Review China 3-6 Sept 2012 06-Sep-2012
Benitec teams with Stanford University on Chronic Pain Research 13-Aug-2012
Chief Investigators Group Update 01-Jun-2012
Technology Update: ddRNAi - The New Therapeutic Revolution? 14-May-2012